All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Stimulating the innate immune system with defective viral genomes (DVG)-based strategy provided broad-spectrum protection against RNA viral infections, including SARS-CoV-2 and other respiratory diseases in animal models, according to a U.S.-led international collaborative study reported in the Nov. 17, 2021, edition of Cell.